YM Biosciences is a biopharmaceutical company engaged in the development of products primarily for the treatment of patients with cancer. Co. conducts and out-sources clinical trials and out-sources the manufacture of clinical materials to third parties. Co. has three product candidates in the clinical stage of development: CYT387, a small molecule pyrimidine kinase inhibitor is used to develop drugs for the inhibition of the JAK2 enzyme; NIMOTUZUMAB, a humanized monoclonal antibody, designed to treat epithelial cancers; and CYT997, a small molecule microtubule polymerization inhibitor, is being developed for the treatment of solid and other tumors in cancer patients.